Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical...

Area of Science:

• Biochemistry
• Pharmacology
• Pathology

Background:

• Matrix metalloproteinase-9 (MMP-9) is crucial for extracellular matrix remodeling and implicated in numerous diseases.
• Previous broad-spectrum MMP inhibitors failed due to lack of selectivity and side effects.
• Current research focuses on indirect MMP-9 modulation using existing therapeutics.

Purpose of the Study:

• To review evidence for MMP-9 modulation by established therapeutics and adjunctive strategies.
• To explore the potential of drug repurposing for MMP-9-related conditions.
• To highlight MMP-9 as a viable therapeutic target.

Main Methods:

• Literature review of studies investigating MMP-9 modulation.
• Analysis of established therapeutics including cardiometabolic, anti-inflammatory, respiratory, and hormone-related agents.
• Inclusion of nutritional interventions and lifestyle factors.

Main Results:

• Cardiometabolic drugs (statins, ACE inhibitors, ARBs, metformin, pioglitazone) reduce MMP-9, aiding vascular protection and insulin sensitivity.
• Anti-inflammatory/respiratory drugs (glucocorticoids, PDE4 inhibitors, macrolides, montelukast, NSAIDs) suppress MMP-9 in lung diseases.
• Tetracyclines (doxycycline), hormone therapies, omega-3 fatty acids, and antioxidants also modulate MMP-9 activity.

Conclusions:

• MMP-9 is a modifiable therapeutic target in various diseases.
• Repurposing approved drugs alongside lifestyle interventions offers safer, context-specific MMP-9 modulation.
• This approach presents novel opportunities for therapeutic intervention.